dpp-4 inhibitors and glp-1 agonists Specific actions of receptor DPP4 for the treatment of pancreatic β-cell impairments in type 2 diabetes fig2.gif

Though these drugs have been deemed effective in treating T2DM, the Food and Drug Administration (FDA) and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints

After treatment, serotonin reuptake transporter (SERT) increased, while tryptophan hydroxylase-1 (TPH-1) decreased in the colon, showing that exendin-4 may reduce pain by regulating SERT and TPH-1 levels

Current data indicate that the vast majority of obese people treated with semaglutide and tirzepatide achieve weight losses of this magnitude (Figure 6)

CAUTION: Consult your physician before use if you are pregnant or nursing, taking medications, undergoing laboratory tests, or have a health condition

7c,d), and that this effect of AITC was inhibited by A967079 (Fig